Intel (INTC) Shareholder Cubic Asset Management Cut Position by $654444 as Valuation Declined …

… 08/05/2018 – SiFive Announces Investment from Intel Capital; 08/05/2018 – Tom’s Hardware: Intel Postpones Patching ‘Spectre NG’ CPU Flaws; …

Intel Corporation (NASDAQ:INTC) Logo

Cubic Asset Management Llc decreased its stake in Intel Corp (INTC) by 8.76% based on its latest 2019Q1 regulatory filing with the SEC. Cubic Asset Management Llc sold 12,348 shares as the company’s stock declined 0.41% . The institutional investor held 128,565 shares of the semiconductors company at the end of 2019Q1, valued at $6.90M, down from 140,913 at the end of the previous reported quarter. Cubic Asset Management Llc who had been investing in Intel Corp for a number of months, seems to be less bullish one the $206.44 billion market cap company. The stock increased 2.19% or $1 during the last trading session, reaching $46.6. About 12.18M shares traded. Intel Corporation (NASDAQ:INTC) has risen 6.00% since August 13, 2018 and is uptrending. It has outperformed by 6.00% the S&P500. Some Historical INTC News: 08/03/2018 – ModusLink Corporation Receives lntel’s Preferred Quality Supplier Award; 19/03/2018 – INTEL CORP – RISA LAVIZZO-MOUREY HAS BEEN ELECTED TO INTEL’S BOARD OF DIRECTORS; 08/05/2018 – SiFive Announces Investment from Intel Capital; 08/05/2018 – Tom’s Hardware: Intel Postpones Patching ‘Spectre NG’ CPU Flaws; 15/05/2018 – PREMIER Announces Intel® Select Solution for uCPE Launch Plans; 07/03/2018 – ASM INTERNATIONAL N.V. RECEIVES INTEL’S PREFERRED QUALITY SUPPLIER AWARD; 15/03/2018 – Asetek: Asetek Announces Ongoing Collaboration with Intel on Liquid Cooling for Servers and Datacenters; 03/04/2018 – TPG TO BUY WIND RIVER FROM INTEL, NO TERMS; 25/04/2018 – China’s upstart chip companies aim to topple Samsung, Intel and TSMC; 21/03/2018 – Intel Editorial: One Simple Truth about Artificial Intelligence in Healthcare: It’s Already Here

First Interstate Bank increased its stake in Pfizer Inc (PFE) by 30.64% based on its latest 2019Q1 regulatory filing with the SEC. First Interstate Bank bought 8,111 shares as the company’s stock declined 4.73% . The institutional investor held 34,583 shares of the health care company at the end of 2019Q1, valued at $1.47M, up from 26,472 at the end of the previous reported quarter. First Interstate Bank who had been investing in Pfizer Inc for a number of months, seems to be bullish on the $196.82 billion market cap company. The stock increased 0.55% or $0.19 during the last trading session, reaching $35.58. About 11.44 million shares traded. Pfizer Inc. (NYSE:PFE) has risen 0.65% since August 13, 2018 and is uptrending. It has outperformed by 0.65% the S&P500. Some Historical PFE News: 08/05/2018 – Mylan says EpiPen supply levels may vary at U.S. pharmacies; 19/03/2018 – ASTELLAS: FDA GRANTS PRIORITY REVIEW FOR SNDA FOR XTANDI; 17/05/2018 – PFIZER: LYRICA MET PRIMARY ENDPOINT IN PEDIATRIC EPILEPSY TRIAL; 23/04/2018 – PFIZER RECEIVED A COMPLETE RESPONSE LETTER; 19/03/2018 – U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC); 07/05/2018 – PFIZER INDIA QTR NET 1.05B RUPEES; 02/05/2018 – NOVARTIS: HEALTH CANADA OKS KISQALI FOR BREAST CANCER; 07/03/2018 – Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference; 10/04/2018 – Pfizer: Recommendation Was Based on Failure to Demonstrate Clear Improvement in Primary Endpoint; 23/04/2018 – MYLOTARG(TM) Approved in the EU for the Treatment of Previously Untreated, De Novo, CD33-positive Acute Myeloid Leukemia in Combination With Chemotherapy

Analysts await Intel Corporation (NASDAQ:INTC) to report earnings on October, 24. They expect $1.18 earnings per share, down 15.71% or $0.22 from last year’s $1.4 per share. INTC’s profit will be $5.23B for 9.87 P/E if the $1.18 EPS becomes a reality. After $1.06 actual earnings per share reported by Intel Corporation for the previous quarter, Wall Street now forecasts 11.32% EPS growth.

Investors sentiment decreased to 0.86 in Q1 2019. Its down 0.14, from 1 in 2018Q4. It dropped, as 61 investors sold INTC shares while 733 reduced holdings. 139 funds opened positions while 541 raised stakes. 2.84 billion shares or 4.15% less from 2.96 billion shares in 2018Q4 were reported. Spinnaker invested in 95,493 shares. Cranbrook Wealth Mngmt Llc holds 0.06% or 3,371 shares. Quantitative Systematic Strategies Limited Liability Company accumulated 0.29% or 21,557 shares. Allsquare Wealth Management Lc holds 8,165 shares or 0.33% of its portfolio. 11,679 were reported by Boothbay Fund Ltd Llc. Fairview Management Ltd Limited Liability Company owns 940,929 shares for 2.7% of their portfolio. Edgemoor Investment Advsr Inc reported 25,320 shares stake. Aureus Asset Management Limited Liability Co owns 25,701 shares. Charles Schwab Inv Advisory Inc reported 4.39M shares. Comm Bancorp owns 0.81% invested in Intel Corporation (NASDAQ:INTC) for 1.28M shares. Nordea Invest Ab holds 0.75% or 6.66M shares. California Pub Employees Retirement Sys stated it has 0.74% of its portfolio in Intel Corporation (NASDAQ:INTC). Farmers has invested 2.12% in Intel Corporation (NASDAQ:INTC). Alpha Windward Ltd reported 6,458 shares. Rice Hall James Assocs Ltd Com accumulated 7,100 shares or 0.01% of the stock.

More notable recent Intel Corporation (NASDAQ:INTC) news were published by: 247Wallst.com which released: “Intel Overtakes Pfizer as Most Shorted Dow Stock – 24/7 Wall St.” on July 25, 2019, also Nasdaq.com with their article: “Intel Breaks Below 200-Day Moving Average – Notable for INTC – Nasdaq” published on August 02, 2019, Benzinga.com published: “Stock Wars: Intel Vs. AMD Vs. Nvidia – Benzinga” on July 26, 2019. More interesting news about Intel Corporation (NASDAQ:INTC) were released by: Benzinga.com and their article: “Analyst: Google Cloud Could Drop Intel For AMD – Benzinga” published on July 30, 2019 as well as Seekingalpha.com‘s news article titled: “Intel’s Outlook May Help Boost Shares – Seeking Alpha” with publication date: July 23, 2019.

Investors sentiment increased to 0.76 in Q1 2019. Its up 0.02, from 0.74 in 2018Q4. It improved, as 66 investors sold PFE shares while 763 reduced holdings. 125 funds opened positions while 501 raised stakes. 3.88 billion shares or 4.26% less from 4.05 billion shares in 2018Q4 were reported. Moreover, Old Point Tru And Fincl N A has 1.75% invested in Pfizer Inc. (NYSE:PFE) for 79,082 shares. Oakwood Cap Mgmt Lc Ca owns 127,162 shares. Stevens First Principles Inv Advsr accumulated 0.88% or 34,786 shares. Kcm Investment Advsrs Ltd Llc holds 153,867 shares. Moreover, Ogorek Anthony Joseph Ny Adv has 0.01% invested in Pfizer Inc. (NYSE:PFE). Cornerstone reported 0.05% in Pfizer Inc. (NYSE:PFE). Cap Mgmt Assoc Ny has 16,383 shares for 1.08% of their portfolio. Proshare Advsr Lc holds 0.29% or 1.14 million shares in its portfolio. London Com Of Virginia stated it has 1.79% in Pfizer Inc. (NYSE:PFE). Parkside Savings Bank Trust invested 0.53% in Pfizer Inc. (NYSE:PFE). Lincluden Mgmt holds 0.66% or 163,008 shares. Edgewood Mgmt Limited Liability Co owns 93,544 shares. Sandler Cap has 0.02% invested in Pfizer Inc. (NYSE:PFE). Alpha Cubed Invests Limited Liability Corp owns 25,900 shares. 438,878 were reported by John G Ullman & Associates Incorporated.

First Interstate Bank, which manages about $448.20M US Long portfolio, decreased its stake in Select Sector Spdr (XLY) by 38,319 shares to 11,649 shares, valued at $1.33M in 2019Q1, according to the filing. It also reduced its holding in Jpmorgan Chase & Co (NYSE:JPM) by 23,990 shares in the quarter, leaving it with 92,083 shares, and cut its stake in Lowe’s Cos Inc (NYSE:LOW).

Pfizer Inc. (NYSE:PFE) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Regal Investment Advisors Has Increased Procter And Gamble Co (PG) Holding By $588744 …

Applied Dna Sciences Inc (APDN) investors sentiment increased to 1 in 2019 Q1. It’s up 0.33, from 0.67 in 2018Q4. The ratio is positive, as 7 active …

The Procter & Gamble Company (NYSE:PG) Logo

Regal Investment Advisors Llc increased Procter And Gamble Co (PG) stake by 7.05% reported in 2019Q1 SEC filing. Regal Investment Advisors Llc acquired 5,661 shares as Procter And Gamble Co (PG)’s stock rose 12.49%. The Regal Investment Advisors Llc holds 85,958 shares with $8.94 million value, up from 80,297 last quarter. Procter And Gamble Co now has $286.68B valuation. The stock increased 1.49% or $1.68 during the last trading session, reaching $114.76. About 4.56M shares traded. The Procter & Gamble Company (NYSE:PG) has risen 47.18% since August 6, 2018 and is uptrending. It has outperformed by 47.18% the S&P500. Some Historical PG News: 18/05/2018 – SIAM CITY CEMENT TO BUY PART OF P.G. SERVICE CO. FOR 195M BAHT; 03/04/2018 – Yahoo! UK: Pfizer in talks with P&G on sale of its consumer business, though far apart on price; 16/04/2018 – PG ELECTROPLAST (PGEL) – OUTCOME OF BOARD MEETING; 22/05/2018 – Procter & Gamble Announces Early Results of Its Debt Tender Offer; Increases the Maximum Tender Amount; 03/04/2018 – 14th Annual Info Security PG’s 2018 Global Excellence Awards® Honors Hillstone Networks with Three Awarded; 19/04/2018 – P&G to Acquire Merck KGaA’s Consumer-Health Unit — 2d Update; 10/04/2018 – P&G DECLARES DIV BOOST; 16/03/2018 – Ranir, LLC vs The Procter & Gamble Company | Terminated-Settled | 03/15/2018; 05/04/2018 – ASCENT RESOURCES PLC ASCR.L – IMPACT OF WORK TO REMOVE WATER AND ALLOW GAS TO FLOW FREELY AT PG-11A IS UNLIKELY TO BE CLEAR FOR SOME TIME; 13/03/2018 – PROCTER & GAMBLE RESOLVES CREST® WHITESTRIPS PATENT

Applied Dna Sciences Inc (APDN) investors sentiment increased to 1 in 2019 Q1. It’s up 0.33, from 0.67 in 2018Q4. The ratio is positive, as 7 active investment managers started new and increased positions, while 7 cut down and sold their stock positions in Applied Dna Sciences Inc. The active investment managers in our database now have: 2.00 million shares, up from 1.80 million shares in 2018Q4. Also, the number of active investment managers holding Applied Dna Sciences Inc in top ten positions was flat from 0 to 0 for the same number . Sold All: 5 Reduced: 2 Increased: 4 New Position: 3.

The stock decreased 7.53% or $0.022 during the last trading session, reaching $0.27. About 324,002 shares traded. Applied DNA Sciences, Inc. (APDN) has declined 78.55% since August 6, 2018 and is downtrending. It has underperformed by 78.55% the S&P500. Some Historical APDN News: 05/04/2018 – APPLIED DNA SCIENCES INC – WILL SUPPLY TAGGANT AND AUTHENTICATION MATERIALS TO COLORCON IN EXCHANGE FOR LONG-TERM ROYALTIES; 05/04/2018 – APPLIED DNA SCIENCES INC APDN.O – AGREEMENTS INCLUDES MILESTONE PAYMENTS. LONG-TERM LICENSING ROYALTIES TO BE PAID TO APPLIED DNA FOLLOWING SALES; 05/04/2018 – Applied DNA Signs Definitive Agreements with Colorcon for Molecular Tagging in the Pharmaceutical and Nutraceutical Markets; 06/04/2018 – APPLIED DNA TEKENT DEFINITIEVE OVEREENKOMSTEN MET COLORCON VOOR MOLECULAIRE MERKING IN DE FARMACEUTISCHE EN NUTRACEUTISCHE MARKT; 03/05/2018 – Applied DNA Sciences 2Q Loss/Shr 7c; 10/04/2018 – Applied DNA to Debut Security Print Platform Solution Featuring Videojet 1860M CIJ Printer at INTERPHEX 2018; 20/03/2018 GHCL Launches “Rekoop” Featuring Applied DNA’s CertainT Platform for the First Line of Source-Verified Recycled Plastic Bedding Products; 23/03/2018 – Applied DNA and Rosier Deliver SigNature®-Tagged Fertilizer to Turkey and Africa; 05/04/2018 – APPLIED DNA SCIENCES INC – AGREEMENTS GENERALLY EXPIRE ON LATER OF OCTOBER 1, 2032 OR LAST EXPIRATION DATE OF ANY PATENT LICENSED UNDER AGREEMENT; 05/04/2018 – APPLIED DNA- TO SECOND MILESTONE PAYMENT ON INITIAL APPROVAL BY REGULATORY AUTHORITY FOR APPLICATION IN SOD PHARMACEUTICAL OR NUTRACEUTICAL PRODUCT APPLICATION

More notable recent Applied DNA Sciences, Inc. (NASDAQ:APDN) news were published by: Finance.Yahoo.com which released: “How Much Of Applied DNA Sciences, Inc. (NASDAQ:APDN) Do Insiders Own? – Yahoo Finance” on July 17, 2019, also Finance.Yahoo.com with their article: “If You Had Bought Applied DNA Sciences (NASDAQ:APDN) Stock Five Years Ago, You’d Be Sitting On A 92% Loss, Today – Yahoo Finance” published on April 29, 2019, Benzinga.com published: “20 Industrials Stocks Moving In Tuesday’s Regular Session – Benzinga” on July 24, 2019. More interesting news about Applied DNA Sciences, Inc. (NASDAQ:APDN) were released by: Businesswire.com and their article: “Applied DNA Schedules Fiscal 2019 Third Quarter Financial Results Conference Call for Tuesday, August 13, 2019 at 4:30 PM ET – Business Wire” published on August 06, 2019 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index – Benzinga” with publication date: July 24, 2019.

Applied DNA Sciences, Inc. provides biotechnology based security solutions for supply chain security, brand protection, and law enforcement applications in the United States, Europe, and Asia. The company has market cap of $10.23 million. The company’s supply chain security and product authentication solutions include SigNature DNA markers that are ingredients used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNature T DNA markers, which are tagging and authentication systems for use in brand protection efforts and raw material source compliance programs; and fiberTyping, a test of native cotton fiber. It currently has negative earnings. It also provides DNAnet, a DNA marker to link evidence and offenders to specific crime scenes; Beacon locked optical markers are encrypted mechanisms, which create a protected covert screening tool that can be adapted to packaging, security labels, and high–value assets through inks, varnishes, and coatings; and SigNify IF portable DNA reader that provides real-time authentication of in the field–DNA.

Chase Investment Counsel Corp holds 0.1% of its portfolio in Applied DNA Sciences, Inc. for 261,163 shares. Bank Of Montreal Can owns 166 shares or 0% of their US portfolio. Moreover, Bank Of New York Mellon Corp has 0% invested in the company for 16,710 shares. The United Kingdom-based Barclays Plc has invested 0% in the stock. Blackrock Inc., a New York-based fund reported 224,385 shares.

More notable recent The Procter & Gamble Company (NYSE:PG) news were published by: Benzinga.com which released: “Procter & Gamble Reports Surging Sales Growth – Benzinga” on July 30, 2019, also Finance.Yahoo.com with their article: “Procter & Gamble (PG) Outpaces Stock Market Gains: What You Should Know – Yahoo Finance” published on July 11, 2019, Finance.Yahoo.com published: “Better Buy: Procter & Gamble vs. Coca-Cola – Yahoo Finance” on July 13, 2019. More interesting news about The Procter & Gamble Company (NYSE:PG) were released by: Businesswire.com and their article: “P&G Declares Quarterly Dividend – Business Wire” published on July 09, 2019 as well as Benzinga.com‘s news article titled: “Procter & Gamble Q4 Earnings Preview – Benzinga” with publication date: July 29, 2019.

Regal Investment Advisors Llc decreased Exelon Corp (Call) (NYSE:EXC) stake by 18,229 shares to 900 valued at $45,000 in 2019Q1. It also reduced Altria Group Inc (Call) (NYSE:MO) stake by 60,023 shares and now owns 400 shares. Chevron Corp New (Call) (NYSE:CVX) was reduced too.

Investors sentiment decreased to 0.78 in 2019 Q1. Its down 0.06, from 0.84 in 2018Q4. It is negative, as 57 investors sold PG shares while 748 reduced holdings. 125 funds opened positions while 506 raised stakes. 1.50 billion shares or 2.71% less from 1.54 billion shares in 2018Q4 were reported. Blume Cap Mngmt owns 1,400 shares or 0.08% of their US portfolio. Mairs & Power reported 264,208 shares. New England Management Inc invested in 0.97% or 13,851 shares. The Connecticut-based Trexquant Invest Limited Partnership has invested 0.08% in The Procter & Gamble Company (NYSE:PG). Regal Investment Advisors Limited Liability Com reported 85,958 shares. Winslow Evans And Crocker accumulated 0.43% or 14,542 shares. Sfmg Ltd Com holds 4,975 shares or 0.07% of its portfolio. Private Harbour Inv Counsel has invested 2.25% in The Procter & Gamble Company (NYSE:PG). Cv Starr & Communications Inc Tru accumulated 80,000 shares. Regentatlantic Capital Limited Liability Com reported 46,541 shares. Moreover, Earnest Lc has 0% invested in The Procter & Gamble Company (NYSE:PG) for 1,200 shares. Botty Invsts Limited Liability Corporation invested in 0.2% or 6,455 shares. New Jersey Better Educational Savings Trust holds 7,000 shares. First Personal Fincl Ser holds 57,146 shares or 1.81% of its portfolio. Welch & Forbes Lc reported 834,045 shares.

Since February 11, 2019, it had 0 buys, and 8 insider sales for $248.77 million activity. The insider PELTZ NELSON sold $119.77 million. Francisco Ma. Fatima also sold $891,000 worth of The Procter & Gamble Company (NYSE:PG) on Tuesday, February 12. Another trade for 22,264 shares valued at $2.20 million was made by Coombe Gary A on Tuesday, February 12. 3,000 shares were sold by Posada Juan Fernando, worth $294,750 on Monday, February 11. The insider Matthew Price sold 20,000 shares worth $1.98 million. Taylor David S sold $2.97M worth of stock.

Among 7 analysts covering Procter & Gamble (NYSE:PG), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Procter & Gamble had 14 analyst reports since February 21, 2019 according to SRatingsIntel. The stock of The Procter & Gamble Company (NYSE:PG) earned “Hold” rating by Deutsche Bank on Wednesday, April 24. The company was maintained on Tuesday, February 26 by Macquarie Research. Morgan Stanley maintained it with “Overweight” rating and $12900 target in Wednesday, July 31 report. The firm earned “Outperform” rating on Monday, April 8 by Wells Fargo. The firm has “Overweight” rating by Barclays Capital given on Wednesday, April 24. On Monday, June 17 the stock rating was maintained by Deutsche Bank with “Hold”. The company was maintained on Thursday, February 21 by Wells Fargo. The stock has “Overweight” rating by Morgan Stanley on Friday, March 29. Goldman Sachs upgraded the stock to “Buy” rating in Friday, June 28 report.

The Procter & Gamble Company (NYSE:PG) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Major Players Operating in the Global Ear Infection Treatment Market from 2019 to 2023

The company offers ZITHROMAX for the treatment of ear infection, which … Global Hearing Aid 3D Printing Devices Market 2019-2023 – The market …

LONDON–(BUSINESSWIRE)–

Ear infections have many risk factors, which include cold and flu season, injury to the ear, bacteria, and cigarette smoke. As there are several ways to contract an ear infection, there is a high demand for ear infection medicine and other treatments. Thus, the high-risk factors of ear infection will fuel the growth of the ear infection treatment market during the forecast period. Furthermore, this industry research report also presents a competitive analysis of the market by geography (North America, Europe, Asia, and ROW) and by infection type (middle ear, outer ear, and inner ear).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190730005542/en/

Technavio has announced its latest market research report titled global ear infection treatment market 2019-2023. (Graphic: Business Wire)

Competitive vendor landscape

The global ear infection treatment market is highly competitive with major vendors such as GlaxoSmithKline, Johnson & Johnson, Novartis, Otonomy, and Pfizer, competing on the basis of price, quality, and market presence.

“Surgery is often the best treatment for patients with chronic ear infections. Thus, companies in the market have been engaging in continuous R&D to develop diagnostic devices and surgical procedures. The development in these areas will make surgical procedures safer and more comfortable, thereby, driving the growth of the ear infection treatment market,” says a senior analyst at Technavio.

Top five ear infection treatment market vendors

GlaxoSmithKline

GlaxoSmithKline is one of the most established companies in the global healthcare that operates under various segments including pharmaceuticals, vaccines, and consumer healthcare. Under its ear infection treatment category, the company offers AMOXIL, and NEOSPORIN H ear drops.

Johnson & Johnson

Johnson & Johnson is a household name across several countries. The company owns and operates businesses under three segments namely consumer, pharmaceutical, and medical devices. The company offers POLYSPORIN + Pain Relief Ear Drops, which contains 10,000 units polymyxin B (as sulfate) and 50 mg lidocaine hydrochloride.

Novartis

Novartis has business operations under three segments, namely innovative medicines, Sandoz, and Alcon. The company offers CIPRODEX ear drops that contain ciprofloxacin and dexamethasone. Ciprofloxacin is an antibiotic that treats certain types of bacteria. Dexamethasone is a steroid drug that reduces inflammation.

Otonomy

Otonomy is engaged in the development of innovative therapeutics for otology. The company’s key offering in the market includes OTIPRIO, which is a sterile, preservative-free, otic suspension of 6% ciprofloxacin administered as a single-dose.

Pfizer

Pfizer owns and operates under two business segments: innovative health and essential health. The company offers ZITHROMAX for the treatment of ear infection, which contains the active ingredient azithromycin, a subclass of macrolide antibiotics, for oral administration. ZITHROMAX tablets contain azithromycin dihydrate equivalent to 600 mg azithromycin.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Browse Related Reports:

  • Global Middle Ear Implants Market 2019-2023 – The market research study identifies Cochlear Ltd., Envoy Medical Corporation, MED-EL Medical Electronics, Medtronic, Olympus Corporation, and Ototronix, as the leading players in the global middle ear implants market.
  • Global Hearing Aid 3D Printing Devices Market 2019-2023 – The market research study identifies 3D Systems Inc., 3Shape AS, EnvisionTEC, Materialise, and Rapid Shape GmbH, as the leading players in the global hearing aid 3D printing devices market.

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190730005542/en/

Contact

Related Posts:

  • No Related Posts

High-Tech Industry Report on Acid Resistant Capsules Market to Access Global Regional Players …

The information, thus presented factors in the different dynamics of business like Acid Resistant Capsules that have been elaborated to get a …

Acid resistant capsule is a kind of capsule that can help protect dietary supplement ingredients from gastric acids. QYReports detailed analysis of its prolific knowledge storehouse titled; Acid Resistant Capsules market has been published. Designed using singular techniques, with detailed employment of primary and secondary research methodologies, the data presented is particular and robust. The information, thus presented factors in the different dynamics of business like Acid Resistant Capsules that have been elaborated to get a comprehensive description of changing variables.

The Acid Resistant CapsulesMarket size is expected to grow at a CAGR of +15% during the forecast period 2019-2025

Request a pdf copy of this report athttps://www.qyreports.com/request-sample/?report-id=216222

By examining economic factors of business, the report thoroughly provides an aerial overview of factors such as Acid Resistant Capsules, which presents access to understand the financial outlook of the industries. Moreover, the detailed report centers on distinctive parameters, crucial to the fundamental understanding of businesses, such as Acid Resistant Capsules. Furthermore, the report provides data on Acid Resistant Capsules, focusing mainly on Acid Resistant Capsules sectors. This in return produces accurate insights to accurately gauge competence of several industries.

Top Key Players are: CapsCanada, Lonza (Capsugel), Natural Capsules Limited, Farmacapsulas, Shanxi Guangsheng, Bright JC Caps, Shanghai HanKing Bio-Techenology

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Hypromellose (HPMC)

Hypromellose Phthalate (HPMCP)

Market Segment by Applications, can be divided into

Health & Nutrition

Pharmaceuticals

Others

Avail 40% Discount on this report athttps://www.qyreports.com/ask-for-discount/?report-id=216222

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Acid Resistant Capsules market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Acid Resistant Capsules market

Enquire Before Buying:

https://www.qyreports.com/enquiry-before-buying/?report-id=216222

Table of Contents

Global Acid Resistant CapsulesMarket Research Report

Chapter 1 Acid Resistant Capsules Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Market Forecast

Conclusion:

Finally, Acid Resistant Capsules Market report is the thinkable source for gaining the market marketing research which will exponentially speed up your business. Therefore, this analysis document can facilitate all the business players and also the readers having a keen interest within the development of this market.

About Us

We at, QYReports, a leading market research report published accommodate more than 4,000 celebrated clients worldwide putting them at advantage in today’s competitive world with our understanding of research. Our list of customers includes prestigious Chinese companies, multinational companies, SME’s and private equity firms whom we have helped grow and sustain with our fact-based research. Our business study covers a market size of over 30 industries offering unfailing insights into the analysis to reimagine your business. We specialize in forecasts needed for investing in a new project, to revolutionize your business, to become more customer centric and improve the quality of output.

Acid Resistant Capsules, Acid Resistant Capsules market, Acid Resistant Capsules market 2025, Acid Resistant Capsules market Analysis, Acid Resistant Capsules market report, Acid Resistant Capsules market Report Analytics, Acid Resistant Capsules market research, Acid Resistant Capsules market Segment, Acid Resistant Capsules market Tred

Related Posts:

  • No Related Posts

Deals Buzz: PhonePe gets ₹698 crore from Singapore parent

Existing investors including Accel Partners, Sequoia Capital, Chiratae Ventures and others are likely to lead the first funding round. This is in line with …

Mumbai:Mint brings you your dose of the top deals news, reported from newsrooms across the country.

PhonePe gets 698 crore from Singapore parent

Flipkart’s digital payments app PhonePe Pvt Ltd (India) has received 698 crore from its parent entity in Singapore called PhonePe Pvt Ltd (Singapore), previously known as Flipkart Payments Pvt Ltd, Mint reported citing filings sourced by business research platform, Paper.vc. PhonePe Singapore infused the funds in the India entity by subscribing to 2,022,946 shares in the latter at 3,440 per piece. This, however, is not the first fund infusion in PhonePe as it had received 763 crore from its parent in March. The capital infusion comes at a time when Flipkart had, nearly two years ago, announced a $500 million funding commitment to the digital payments app to boost its operations. PhonePe was valued at $1.5 billion valuation at the time Walmart bought 77% of the Flipkart group at a total valuation of around $21 billion. Investment advisory firm KeyBanc Capital Markets said in a 24 June note that Walmart’s stake in PhonePe alone could be worth more than $14 billion in the medium term.

BigBasket secures 100 crore debt investment from Trifecta Capital

Online grocer BigBasket received debt funding worth 100 crore from venture debt provider Trifecta Capital, Mint reported citing a statement from SuperMarket Grocery Supplies Pvt. Ltd, which owns and operates BigBasket. The money will go into working capital and capital expenditure requirements, which includes setting up of new warehouses, strengthening the cold chain, building facilities for reprocessing fruits and vegetables and scaling up its supply chain for the recently launched milk subscription business BB Daily and its speciality vending machine business BB Instant. The deal announcement comes two months after BigBasket raised $150 million in a financing round led by South Korea’s Mirae Asset-Naver Asia Growth Fund, UK’s CDC Group, and existing investor Alibaba. The company was valued just over $1 billion at that time. The latest investment into Bigbasket is one of the largest debt deals in India’s consumer internet industry this year, according to multiple investment analysts that Mint spoke to.

Pfizer to merge generics unit with Mylan

Drugmaker Pfizer Inc has agreed to spin off its generic drugs business and combine it with Mylan, a move that leaves Pfizer with more profitable innovative drugs, including cancer drug Ibrance and pneumonia vaccine Prevnar, Mint filed from a Reuters feed. The new company, to be based in the United States and incorporated in Delaware, will be led by Michael Goettler, president of Pfizer’s generics unit, Upjohn. The move is part of a years-long effort by Pfizer to split into three parts – innovative medicines, lower margin generic drugs business and consumer healthcare. While the merger brings blockbuster treatments Viagra, EpiPen and Lipitor under one umbrella, Pfizer has also been beefing up its cancer treatment pipeline as some of its older treatments face competition. Besides, Pfizer and GlaxoSmithKline Plc had said in December they would combine their consumer health businesses.

Comcast-led group makes offer to buy out Zee promoters

A consortium led by US cable major Comcast, which also includes Atairos, Blackstone and James Murdoch’s Lupa Systems submitted a binding offer late Monday to buy out Subhash Chandra from Zee Entertainment, The Economic Times reported citing people aware of the development. Sources close to Zee, however, said they had not received any bid till late Monday evening. Zee’s promoters own 35.79% of the company, of which 63.98% has been pledged with mutual funds and other financial institutions. At current market price, the promoters’ stake is worth 13,315 crore (around $1.92 billion), which may be sold at a 15-20% control premium over the market value. The transaction, if accepted, will also likely trigger an open offer for an additional 26% stake and would need board’s approval before a deal is finalised. The deal will give a breather to Chandra, whose Essel Group is facing a severe debt crisis. Chandra had last year announced plans to sell half the promoters’ stake, then 41%, in the company.

Scooter sharing app Bounce looks to raise $30 million

Scooter sharing app Bounce plans to raise $30 million separately for its electric vehicles subsidiary, Zuink Smart Mobility Solutions, and has received in-principle board approval for the same, The Economic Times reported citing two people aware of the development. Existing investors including Accel Partners, Sequoia Capital, Chiratae Ventures and others are likely to lead the first funding round. This is in line with its plan to build a distributed infrastructure for EVs using kirana stores, and to deploy battery swapping stations across cities. Bounce, which is running a pilot with nearly 30 kirana owners in the city, plans to connect them with banks and other lenders to finance charging units and EV batteries. The cost per station works out to 100,000, according to Vivekananda Hallekere, CEO and co-founder, Bounce.

MindTickle raises $40 million funding Norwest Venture Partners

Sales enablement platform MindTickle raised $40 million in fresh funding, led by US-based venture capital fund Norwest Venture Partners, The Economic Times reported. The series C round also saw participation from existing investors Accel Partners, Canaan Partners, New View Capital – a spin out of New Enterprise Associates, and Qualcomm Ventures. Post the investment, Scott Beechuk, partner at Norwest Venture Partners, will also join the startup’s board as part of the deal. The software-as-a-service (SaaS) firm, based out of Silicon Valley and Pune, will utilise the funding to strengthen its products and expand outside the US into Europe and Southeast Asia in the coming months.

Related Posts:

  • No Related Posts